Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome Jan 22, 2019
Aurinia to Hold Conference Call and Webcast to Discuss Results of Phase 2 Head-to-Head Study of Voclosporin Ophthalmic Solution versus Restasis® for the Treatment of Dry Eye Syndrome Jan 21, 2019
Aurinia to Present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco Dec 19, 2018
Aurinia Reports Third Quarter Financial Results, Clinical Highlights and Corporate Development Nov 8, 2018
Aurinia Pharmaceuticals to Release Third Quarter Financial Results and General Business Updates on November 8, 2018 Oct 25, 2018
Aurinia Completes Enrollment of AURORA, its Phase 3 Clinical Trial for the Treatment of Lupus Nephritis Sep 25, 2018
Aurinia Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018 Aug 28, 2018
